Abstract
Radiation-induced lung fibrosis (RILF) is a severe side effect of radiotherapy in lung cancer patients that presents as a progressive pulmonary injury combined with chronic inflammation and exaggerated organ repair. RILF is a major barrier to improving the cure rate and well-being of lung cancer patients because it limits the radiation dose that is required to effectively kill tumor cells and diminishes normal lung function. Although the exact mechanism is unclear, accumulating evidence suggests that various cells, cytokines and regulatory molecules are involved in the tissue reorganization and immune response modulation that occur in RILF. In this review, we will summarize the general symptoms, diagnostics, and current understanding of the cells and molecular factors that are linked to the signaling networks implicated in RILF. Potential approaches for the treatment of RILF will also be discussed. Elucidating the key molecular mediators that initiate and control the extent of RILF in response to therapeutic radiation may reveal additional targets for RILF treatment to significantly improve the efficacy of radiotherapy for lung cancer patients.
Keywords: Fibrosis, lung cancer, radiotherapy, side effects.
Current Drug Targets
Title:Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis
Volume: 14 Issue: 11
Author(s): Nian-Hua Ding, Jian Jian Li and Lun-Quan Sun
Affiliation:
Keywords: Fibrosis, lung cancer, radiotherapy, side effects.
Abstract: Radiation-induced lung fibrosis (RILF) is a severe side effect of radiotherapy in lung cancer patients that presents as a progressive pulmonary injury combined with chronic inflammation and exaggerated organ repair. RILF is a major barrier to improving the cure rate and well-being of lung cancer patients because it limits the radiation dose that is required to effectively kill tumor cells and diminishes normal lung function. Although the exact mechanism is unclear, accumulating evidence suggests that various cells, cytokines and regulatory molecules are involved in the tissue reorganization and immune response modulation that occur in RILF. In this review, we will summarize the general symptoms, diagnostics, and current understanding of the cells and molecular factors that are linked to the signaling networks implicated in RILF. Potential approaches for the treatment of RILF will also be discussed. Elucidating the key molecular mediators that initiate and control the extent of RILF in response to therapeutic radiation may reveal additional targets for RILF treatment to significantly improve the efficacy of radiotherapy for lung cancer patients.
Export Options
About this article
Cite this article as:
Ding Nian-Hua, Li Jian Jian and Sun Lun-Quan, Molecular Mechanisms and Treatment of Radiation-Induced Lung Fibrosis, Current Drug Targets 2013; 14 (11) . https://dx.doi.org/10.2174/13894501113149990198
DOI https://dx.doi.org/10.2174/13894501113149990198 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Sumoylation in Cellular Senescence and Aging
Current Molecular Medicine Construction and Analysis of mRNA and lncRNA Regulatory Networks Reveal the Key Genes Associated with Prostate Cancer Related Fatigue During Localized Radiation Therapy
Current Bioinformatics A Review on the Synthesis and Anti-cancer Activity of 2-substituted Quinolines
Anti-Cancer Agents in Medicinal Chemistry The Genome as a Drug Target Sequence Specific Minor Groove Binding Ligands
Current Drug Targets Phytochemicals for Breast Cancer Therapy: Current Status and Future Implications
Current Cancer Drug Targets Development and Application of Fourier-Transform Infrared Chemical Imaging of Tumour in Human Tissue
Current Medicinal Chemistry Navigational Bronchoscopy in the Evaluation of the Peripheral Pulmonary Nodule.
Current Respiratory Medicine Reviews Synthesis and Biological Activities of Organotin(IV) Complexes as Antitumoral and Antimicrobial Agents. A Review
Mini-Reviews in Medicinal Chemistry Targeted Drugs and Nanomedicine: Present and Future
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomarkers New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Withdrawal Notice: Application of Nanomaterials in Development of Electrochemical Sensors and Drug Delivery Systems for Anticancer Drugs
Current Drug Delivery Riluzole Inhibits Proliferation, Migration and Cell Cycle Progression and Induces Apoptosis in Tumor Cells of Various Origins
Anti-Cancer Agents in Medicinal Chemistry Treatment Strategy Issues for Chronic HIV-1 Infection in Adults: The Dilemma of Life-long Antiretroviral Treatment
Current Medicinal Chemistry - Anti-Infective Agents The Novel VEGF<sub>121</sub>-VEGF<sub>165</sub> Fusion Attenuates Angiogenesis and Drug Resistance via Targeting VEGFR2-HIF-1α-VEGF<sub>165</sub>/Lon Signaling Through PI3K-AKT-mTOR Pathway
Current Cancer Drug Targets Multifunctional Hydroxyapatite-based Nanoparticles for Biomedicine: Recent Progress in Drug Delivery and Local Controlled Release
Current Mechanics and Advanced Materials Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers Differential Expressions of Matrix Metalloproteinases, A Disintegrin and Metalloproteinases, and a Disintegrin and Metalloproteinases with Thrombospondin Motifs and their Endogenous Inhibitors Among Histologic Subtypes of Lung Cancers
Anti-Cancer Agents in Medicinal Chemistry Avian Cytokines - An Overview
Current Pharmaceutical Design